AlvotechALVOReports Wed, Nov 11 · Nine months and Q3 2026
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · Iceland · alvotech.com
Reykjavik-based global biotechnology company specialising in the development and manufacture of biosimilar medicines for worldwide markets. Its Nasdaq line is the primary listing, with secondary listings in Stockholm and Iceland.
Key ratios
FCF / Sales
-19.5%2025
2024
-59.0%2023
-369.9%
Net margin
-36.3%TTM
2025
4.7%2024
-47.1%
ROA
2.2%TTM
2025
3.8%2024
4.1%2023
-19.0%
Revenue growth
19.7%2025
2024
426.8%2023
9.8%
Recent news
Alvotech to Present at Upcoming Investor Conferences in November
Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026
Alvotech Receives FDA Approval for New SIMLANDI Manufacturing Process That More Than Doubles Output Per Batch
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply
FDA approves additional U.S. manufacturing capacity for SIMLANDI, Alvotech's biosimilar to Humira
Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio to Subcutaneous Presentations
Alvotech to present at upcoming investor conferences in September
Track ALVO in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer